Antitumor vaccination with HER-2-derived recombinant antigens

✍ Scribed by Damir Vidovic; Thomas Graddis; Feng Chen; Paul Slagle; Michael Diegel; Lara Stepan; Reiner Laus

• Book ID: 102268619
• Publisher: John Wiley and Sons
• Year: 2002
• Tongue: French
• Weight: 105 KB
• Volume: 102
• Category: Article
• ISSN: 0020-7136
• DOI: 10.1002/ijc.10785

✦ Synopsis

Abstract

Certain types of malignant tumors overexpress HER‐2, a transmembrane glycoprotein of the class I receptor tyrosine kinase erbB family. To develop an effective HER‐2 vaccine for the selective immunotherapy of these malignancies, we have genetically engineered fusion proteins containing portions of extra‐ and intracellular HER‐2 domains. Activated dendritic cells (DC) cocultured with these novel antigens (Ag) could induce potent responses of Ag‐specific T‐cell lines in vitro and a protection against HER‐2‐expressing tumor in vivo. The protective capabilities of HER‐2‐derived fusion proteins correlated with the efficiency of their presentation to Ag‐specific T‐cell hybridomas. The most effective Ag contained GM‐CSF, the presence of which facilitated their internalization by antigen‐presenting cells (APC) in a receptor‐mediated manner. © 2002 Wiley‐Liss, Inc.